m-PEG11-acid |
| Katalog-Nr.GC65040 |
m-PEG11-SÄure ist ein nicht spaltbarer PEG-ADC-Linker mit 11 Einheiten, der bei der Synthese von AntikÖrper-Wirkstoff-Konjugaten (ADCs) verwendet wird. m-PEG11-SÄure ist auch ein PEG-basierter PROTAC-Linker, der bei der Synthese von PROTACs verwendet werden kann.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2280998-74-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
m-PEG11-acid is a non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. m-PEG11-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[2].
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
[1]. Wilfried Braje et al. Macrocyclic mcl-1 inhibitors and methods of use. WO2019035927A1.
[2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *